Vertex's Journavx got FDA approval for acute pain but faces adoption challenges. Click here to read more about VRTX stock and ...

But one tiny U.K. startup founded by a team of former Palantir engineers thinks it can beat these behemoths to become the ...

Thank you for standing by for the Alphabet fourth quarter and fiscal year 2024 earnings conference call. At this time, all ...

From packable sleeping pads to ultracomfortable air beds, we tested and found the best camping mattresses and sleeping pads ...

Self-healing roads, made from biomass waste and designed using AI, could offer a solution to the country’s £143 million ...

AI is built on data that records information about society. We live in a society that is unfortunately inherently biased, and ...

Vertex just won approval for a drug to treat one of the most common health problems -- pain. The biotech company is offering an option for patients and doctors who don’t want to go for ...

The U.S. Food and Drug Administration approved a new prescription-strength pain reliever from Vertex Pharmaceuticals on Jan. 30, 2025. Journavx is a non-opioid drug that prevents peripheral nerves ...

Concrete's strength and structural integrity come not only in its material properties, but also from how it's molded during construction. An architecture student has devised a clever way to build ...

UnitedHealthcare likely to cover Vertex’s pain drug Vertex Pharmaceuticals received FDA approval for a new non-opioid pain drug, marketed as Journavx, and it appears the nation’s largest ...

Three proposals are being considered to fill the empty lot at 21 S. Linn Street, including plans for entertainment and affordable housing.

Located at 350 Park Avenue, the 62-story office tower—developed by Vornado Realty Trust, Rudin, and Citadel—will replace ...